Cytokinetics Inc. Stock
Cytokinetics Inc. Stock
A loss of -1.320% shows a downward development for Cytokinetics Inc..
The stock is one of the favorites of our community with 31 Buy predictions and 1 Sell predictions.
As a result the target price of 83 € shows a very positive potential of 85.27% compared to the current price of 44.8 € for Cytokinetics Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Cytokinetics Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Cytokinetics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
B****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cytokinetics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cytokinetics Inc. | -1.320% | -18.198% | -26.179% | 31.977% | -40.654% | 138.947% | - |
| Ardelyx Inc. | -3.280% | -3.853% | 15.454% | 108.097% | 19.170% | 20.842% | - |
| Evolus Inc | -5.830% | 2.564% | 13.208% | 34.078% | 32.597% | 61.074% | - |
| Salarius Pharmaceuticals Inc. | 5.580% | 3.141% | -10.860% | -67.167% | -29.009% | -98.470% | -99.993% |
Comments
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at HC Wainwright from $94.00 to $90.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at Barclays PLC from $100.00 to $95.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at Raymond James from $92.00 to $70.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CYTK provided by MarketBeat